Volume 32, Issue 12 | CNS Drugs

Home
CNS Drugs
Volumes and issues
Volume 32, Issue 12

CNS Drugs

Publishing model:: Hybrid

Submit your manuscript

Search all CNS Drugs articles

Volume 32, Issue 12

December 2018

Filter by

Volume:

Sort by

Date published:

New to old Old to new

11 articles in this issue

Acknowledgement to Referees

Acknowledgement to Referees 20 November 2018 Pages: 1079 - 1083
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Jacoline C. Bouvy
Pall Jonsson
John Gallacher
Current Opinion Open access 22 November 2018 Pages: 1085 - 1090
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust
Agne Taraseviciute
Cameron J. Turtle
Leading Article 01 November 2018 Pages: 1091 - 1101
Part of 1 collection:

CNS oncology
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis
Pierre Ellul
Richard Delorme
Samuele Cortese
Systematic Review 20 September 2018 Pages: 1103 - 1112
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
Maira Aguiar Werneck
Guilherme Trevizan Kortas
João Mauricio Castaldelli-Maia
Systematic Review 25 October 2018 Pages: 1113 - 1129
Part of 1 collection:

Cannabinoids in Neurology and Psychiatry
VMAT2 Inhibitors in Neuropsychiatric Disorders
Arjun Tarakad
Joohi Jimenez-Shahed
Review Article 10 October 2018 Pages: 1131 - 1144
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
Marita Zimmermann
Elizabeth Brouwer
Josh J. Carlson
Original Research Article 23 August 2018 Pages: 1145 - 1157
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
Alexander Klistorner
Yi Chai
RENEW MF-VEP Investigators
Original Research Article Open access 28 September 2018 Pages: 1159 - 1171
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
Mark Gudesblatt
Karl Wissemann
Lily Lee
Original Research Article Open access 24 August 2018 Pages: 1173 - 1181
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
Mark Gudesblatt
Karl Wissemann
Lily Lee
Correction 22 September 2018 Pages: 1183 - 1183
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
John A. Hey
Petr Kocis
Martin Tolar
Correction 12 November 2018 Pages: 1185 - 1185